Your browser doesn't support javascript.
loading
Synthesis of the GPR40 Partial Agonist MK-8666 through a Kinetically Controlled Dynamic Enzymatic Ketone Reduction.
Hyde, Alan M; Liu, Zhijian; Kosjek, Birgit; Tan, Lushi; Klapars, Artis; Ashley, Eric R; Zhong, Yong-Li; Alvizo, Oscar; Agard, Nicholas J; Liu, Guiquan; Gu, Xiuyan; Yasuda, Nobuyoshi; Limanto, John; Huffman, Mark A; Tschaen, David M.
Afiliação
  • Hyde AM; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Liu Z; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Kosjek B; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Tan L; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Klapars A; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Ashley ER; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Zhong YL; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Alvizo O; Codexis Inc., Redwood City, California 94063, United States.
  • Agard NJ; Codexis Inc., Redwood City, California 94063, United States.
  • Liu G; Shanghai SynTheAll Pharmaceutical Co., Ltd., Jinshan District, Shanghai 201507, China.
  • Gu X; Shanghai SynTheAll Pharmaceutical Co., Ltd., Jinshan District, Shanghai 201507, China.
  • Yasuda N; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Limanto J; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Huffman MA; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Tschaen DM; Process R&D Department, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Org Lett ; 18(22): 5888-5891, 2016 11 18.
Article em En | MEDLINE | ID: mdl-27802043
ABSTRACT
A scalable and efficient synthesis of the GPR40 agonist MK-8666 was developed from a simple pyridine building block. The key step to set the stereochemistry at two centers relied on an enzymatic dynamic kinetic reduction of an unactivated ketone. Directed evolution was leveraged to generate an optimized ketoreductase that provided the desired trans alcohol in >301 dr and >99% ee. Further, it was demonstrated that all four diastereomers of this hydroxy-ester could be prepared in high yield and selectivity. Subsequently, a challenging intramolecular displacement was carried out to form the cyclopropane ring system with perfect control of endo/exo selectivity. The endgame coupling strategy relied on a Pd-catalyzed C-O coupling to join the headpiece chloropyridine with the benzylic alcohol tailpiece.
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Org Lett Assunto da revista: BIOQUIMICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Org Lett Assunto da revista: BIOQUIMICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos